• Represented ANE (Cayman) Inc., a leading express freight network operator in China’s less-than-truckload market, in its HK$1.1billion global offering and initial public offering on the Main Board of the Hong Kong Stock Exchange. J.P. Morgan and CICC acted as the joint sponsors of this transaction.*
• Represented China Youran Dairy Group Limited, one of the largest integrated providers of products and services in the upstream dairy industry in China, in its HK$5 billion global offering and initial public offering on the Main Board of the Hong Kong Stock Exchange. Huatai Securities and Credit Suisse acted as the joint sponsors, and together with Citigroup and CLSA acted as the joint global coordinators of this transaction.*
• Represented Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company, in its HK$549 million global offering and initial public offering on the Main Board of the Hong Kong Stock Exchange. Goldman Sachs and CICC acted as the joint sponsors, and together with CMBI and CLSA acted as the joint global coordinators of this transaction.*
• Represented Kindstar Globalgene Technology, Inc., a leading independent esoteric clinical testing service provider in China, in its HK$2.21 billion global offering and initial public offering on the Main Board of the Hong Kong Stock Exchange. Goldman Sachs, CICC and Credit Suisse acted as the joint sponsors of this transaction.*
• Represented CICC and CMS as the joint sponsors in the HK$813 million global offering and initial public offering of China Tobacco International (HK) Company Limited, the designated offshore platform of China Tobacco International Inc. for capital markets operation and international business expansion, on the Main Board of the Hong Kong Stock Exchange.*
• Advising Hong Kong-listed companies, including Meituan, ANE (Cayman) Inc., and CANbridge Pharmaceuticals Inc., on post-listing compliance matters.*

* Including projects involved in prior to joining Paul Hastings